Phase III
Patients who received Tecentriq and Avastin in addition to standard chemo showed a 38 percent reduction in the risk of the disease getting worse or death.
ASIT biotech has received positive feedback from the FDA on the preparation of the clinical development plan for gp-ASIT+ in the U.S., with only a few comments and the request for some clarification on the Master File.
Shares of Ultragenyx are sharply climbing this morning after the company announced positive results from its Phase III study of burosumab in adults with XLH.
Sanofi terminated an experimental Clostridium difficile vaccine after an Independent Data Monitoring Committee concluded the Phase III trial was unlikely to hit its endpoints.
In an analysis of BMS’ recent clinical history, Industry analysts at Trefis noted that two oncology drugs will be key revenue drivers for the company.
Bristol-Myers Squibb has its eyes set on carving out a strong position in the lucrative Chinese lung cancer market.
An IDMC told Bayer that it should unblind its Phase III clinical trial in prostate cancer in order to further analyze an increased number of fractures and deaths.
Migraine sufferers may find some new relief as Amgen unveiled results from a late-stage study that shows its Phase III drug Aimovig reduced monthly migraine attacks in half.
Nobody is interested in slow-growth or no-growth stocks, long term or short term, but everyone’s interested in fast-growing stocks.
With the $63.5B takeover of Monsanto by Bayer taking longer than expected, and a key patent for Xarelto expiring in 2024, Bayer’s execs are finding themselves defending their decisions.
PRESS RELEASES